Greetings from Tom Moore! I’m the Chairman and CEO of Advaxis, a clinical-stage biotechnology company that is enthusiastic about what we do.

I want to share with you what makes our company unique among next generation immunotherapies- our technology and our people. This blog is intended to provide insight into recent developments in biotechnology and where we fit in the expanding biopharmaceutical landscape.

Technology can be as reflective of cultural change as fashion or politics. Immunotherapy’s focus on helping the body heal itself appeals to our current appreciation of the organic, the holistic, and our higher standards for quality of life during treatment.

Chemotherapy, radiation, and surgery can be effective against cancer, but can come at a great cost to the patient. The American Cancer Society cautions that chemotherapy and radiation can have long-lasting side effects over months or years.[1] The next generation of cancer treatments is intended to be as effective while more narrowly targeting the rapidly dividing cells that characterize cancer.

As the 17th century Spanish writer Baltasar Gracián said, “You may be obliged to wage war, but not to use poison arrows.”[2] Refocusing immune defenses to fight tumor cells has the potential to be highly effective, specific in its attack, and with less collateral cellular damage. It’s ironic that three immunologists recently awarded the Nobel Prize would be given an award named after the man who invented dynamite. Immunotherapies are designed to be the opposite of a general blasting away at cancer, as we have had to do to date.

The first generation of immunotherapies has been focused on harnessing the body’s defense mechanisms. The goal of the next generation is to develop immunotherapies that further diminish side effects. “Do no harm” is an oath as old as the medical profession, but the next generation of immunotherapies is truly taking that notion to heart.

Check back in for my periodic posts.

Thank you,

Tom Moore

Past Events

LD Micro 4^th Annual Conference
Presentation by Mark Rosenblum, CFO of Advaxis
December 7^th-8^th, 2011
Los Angeles, CA

ADXS-HPV Project Selected as One of the Windhover and Campbell Alliance 2011 Top 10 Most Interesting Oncology Projects to Watch Presentation
Therapeutic Area Partnerships Conference
November 30^th-December 2^nd, 2011
Boston, MA

BIO 10^th Annual Investor Forum Presentation
October 25^th, 2011, 9.30am PST
San Francisco, CA
Webcast

Society for Immunotherapy of Cancer 26^th Annual Meeting Poster
“ADXS11-001, Lm-LLO Immunotherapy Targeting HPV-E7: Preliminary Safety Data From Two Phase 2 Studies in Women with CIN 2/3 and with Recurrent/Refractory Cervical Cancer”
Lead Authors: Dr. Keith Aqua, Dr. Partha Basu, Dr. Robert Petit
November 4^th-6^th, 2011
North Bethesda, MD
Download Poster

Advaxis Annual Meeting
Presentation by Tom Moore, CEO of Advaxis
September 27^th, 2011, 10am EST
Princeton, NJ
Download Slides

Rodman & Renshaw 13^th Annual Healthcare Conference
Presentation by Tom Moore, CEO of Advaxis
September 11^th-13^th, 2011
New York, NY
Webcast

National Investment Banking Association
Interview with Tom Moore, CEO of Advaxis
June 15^th-17^th, 2011
Atlanta, GA
Video

OneMedForum Emerging Company Finance Conference
January 9th-11th, 2012
San Francisco, CA

AACR New Horizons in Cancer Research: Biology to Prevention to Therapy Conference Poster
“ADXS11-001 immunotherapy targeting HPV-E7: Preliminary safety data from a phase 2 study in Indian women with recurrent/refractory cervical cancer”
Lead Authors: Dr. Partha Basu, Dr. Robert Petit
December 16^th, 2011
Leela Kempinski Gurgaon
Gurgaon, Delhi (NCR), India
Download Poster

AACR New Horizons in Cancer Research: Biology to Prevention to Therapy Conference, Plenary Session on Cervical Cancer Presentation
Presentation by Dr. Partha Basu, Investigator in ADXS-HPV cervical cancer trial in India
December 14^th, 2011
Leela Kempinski Gurgaon
Gurgaon, Delhi (NCR), India

Princeton, NJ – November 15, 2011 – Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has exclusively licensed the use of antigen ISG15 in Advaxis’ Lm-LLO based immunotherapies from the University of Pennsylvania. This intellectual property resulted from research conducted in Dr. Yvonne Paterson’s laboratory that demonstrated ISG15 was an effective immunological target for the treatment of breast cancer in animal models.

“Targeting ISG15 may represent a therapeutic approach suitable for a population of patients with advanced breast cancer for whom few approved treatments currently exist. The research conducted by Dr. Paterson and colleagues, as well as research conducted at other institutions, suggests that this antigen may have utility in treating other tumor types as well. ISG15 is Advaxis’ first proprietary antigen,” said Dr. John Rothman, Executive Vice President, Science & Operations.

About Antigen ISG15

ISG15 is a novel protein associated with numerous cancers. Recently published data demonstrate that Advaxis’ Lm-LLO immunotherapy reduced primary and metastatic breast tumors in an animal model when directed against ISG15. “The Ubiquitin-like Protein, ISG15, is a Novel Tumor-Associated Antigen for Cancer Immunotherapy,” (Wood, LM, Pan, ZK, Seavey, MM, Muthukumaran, G, and Paterson, Y. 2011, Cancer Immunol Immunother).

About Advaxis, Inc.

Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live attenuated Listeria monocytogenes (Lm) that are bio-engineered to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to Lm to the cancer itself.

ADXS-HPV, Advaxis’ first construct to reach the clinic is being evaluated in 4 Phase 2 clinical trials for HPV-associated diseases (CIN 2/3, cervical cancer, and head & neck cancer) with over 130 patients dosed to date. Over fifteen (15) distinct constructs are in various stages of development, either developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, and the University of Pennsylvania, among others. For more information please visit: advaxis.com | Facebook | twitter | LinkedIn

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements as to the anticipated timing of clinical studies and other business developments, statements as to the development of new constructs, expectations as to the adequacy of our cash balances to support our operations for specified periods of time and as to the nature and level of cash expenditures, expectations as to market opportunities, our ability to take advantage of those opportunities, and the risk factors set forth from time to time in Advaxis’ SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2010, which is available at http://www.sec.gov. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

For Further Information:

Diana Moore
Director, Investor Relations & Business Development
Advaxis, Inc.
dmoore@advaxis.com
609.452.9814

Princeton, NJ – October 28, 2011 – Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has entered into a definitive Convertible Notes Purchase Agreement (Agreement) for the purchase of the aggregate principal value of approximately $2.3 million of Convertible Promissory Notes (Notes) for an aggregate purchase price of approximately $2.0 million. Investors include certain accredited investors as well as the CEO and the CFO of the Company.  The Notes purchased in the offering shall be paid for in cash or, with respect to Notes acquired by Advaxis Chairman/CEO Thomas A. Moore, in exchange for the cancellation of $400,000 of outstanding indebtedness owed by the Company.  The closing of the sale of the Notes, under the Agreement, is anticipated to occur on or about October 31, 2011, subject to customary closing conditions.

The Notes have an original issue discount of 15% and mature on the one year anniversary of the issue date. Under the terms specified therein, the Notes are convertible, in whole or in part, into common stock at a conversion price of $.15. However, except as otherwise provided in the Notes, only 85% of the initial principal amount of each Note is convertible at any time after issuance and the remainder is convertible at maturity.

In connection with the Agreement, the Company issued a warrant to each investor to acquire up to such number of shares of Common Stock equal to 50% of such number of Conversion Shares, issuable upon exercise of the Note issued to such Investor as of the Closing Date with an exercise price of $0.15. The warrants will expire in three years. Pursuant to a Registration Rights Agreement between the Company and the investors, the Company is required to file a resale registration statement within 30 days that covers the resale of the underlying shares of both the Notes and shares issuable upon exercise of the warrants.

“This financing will provide additional operating funds between now and the announcement of interim results for our Phase 2 clinical trial on cervical cancer currently underway in India. I am particularly pleased that many of those supporting this financing have invested in the company previously,” commented Advaxis Chairman/CEO Thomas A. Moore. “This small group of investors also includes the company’s chief financial officer and myself.”

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc., (NASDAQ: RODM), acted as the exclusive placement agent for the transaction. For more information, please visit www.rodm.com.

A summary of the transaction will be included in the Company’s Current report on Form 8-K to be filed with the Securities and Exchange Commission.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any securities of the Company. The securities offered and sold in the private placement have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration under the Securities Act and applicable state securities laws.

About Advaxis, Inc.

Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live attenuated Listeria monocytogenes (Lm) that are bio-engineered to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to Lm to the cancer itself.

ADXS-HPV, Advaxis’ first construct to reach the clinic is being evaluated in 4 Phase 2 clinical trials for HPV associated diseases (CIN 2/3, cervical cancer, and head & neck cancer) with over 130 patients dosed to date. Over fifteen (15) distinct constructs are in various stages of development, either developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others. For more information please visit: advaxis.com | Facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties.  The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance.  Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company’s actual results in future periods to differ materially from what is currently anticipated.  Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission.  The Company cannot guarantee its future results, levels of activity, performance or achievements.

For Further Information:

Diana Moore

Director, Investor Relations & Business Development

Advaxis, Inc.

dmoore@advaxis.com

609.452.9814

Princeton, NJ – October 18, 2011 – Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a US Patent titled “Compositions and Methods for Treatment of Cervical Cancer.” This patent specifically protects the use of the Advaxis HPV construct for the treatment of late stage cervical cancer, an unmet medical need for which this agent is currently being evaluated in 2 Phase II clinical trials, two of which are in recurrent metastatic cervical cancer, one in India and one in collaboration with the Gynecologic Oncology Group of the National Cancer Institute in the US.

Once issued, this patent will provide a new 17+ year patent cycle for Advaxis’ lead compound.

This patent establishes ADXS-HPV as a method of treatment for late stage cervical cancer in human patients using a recombinant Listeria strain comprised of a fusion of HPV E7 antigen and an N-terminal fragment of an LLO protein.

This patent also protects ADXS-HPV in various physical formulations, including a dried formulation that is stable at room temperature.

The subject matter of this patent is based on the work of Dr. Yvonne Paterson and Dr. John Rothman and is assigned to both the University of Pennsylvania and Advaxis. Together, Advaxis and the University of Pennsylvania hold over 70 approved patents and pending patent applications for composition of matter and methods of use.

About Advaxis, Inc.

Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live attenuated Listeria monocytogenes (Lm) that are bio-engineered to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to Lm to the cancer itself.

ADXS-HPV, Advaxis’ first construct to reach the clinic is being evaluated in 4 Phase 2 clinical trials for HPV associated diseases (CIN 2/3, cervical cancer, and head & neck cancer) with over 130 patients dosed to date. Over fifteen (15) distinct constructs are in various stages of development, either developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others. For more information please visit: advaxis.com | Facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties.  The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance.  Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company’s actual results in future periods to differ materially from what is currently anticipated.  Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission.  The Company cannot guarantee its future results, levels of activity, performance or achievements.

For Further Information:

Diana Moore

Director, Investor Relations & Business Development

Advaxis, Inc.

dmoore@advaxis.com

609.452.9814

Princeton, NJ – October 17, 2011 – Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, today announced that Tom Moore, Chairman and Chief Executive Officer, will present at the 10^th Annual BIO Investor Forum on Tuesday, October 25th in San Francisco.

Advaxis’ presentation will begin at 9:30 a.m. PST. A live webcast of the presentation will be available on the Company’s website at www.advaxis.com.

About the 10^th Annual BIO Investor Forum 

The 10th Annual BIO Investor Forum assembles a select group of public and venture-stage growth companies, as well as top public and private equity investors, to explore investment trends and opportunities in life sciences. In addition to expert-led workshops and panel discussions focusing on industry trends, the conference features presentations by over 100 biotech companies poised to join the growth “watch list” in 2011, as well as a number of nonprofit and venture philanthropy organizations. For more information, please visit the BIO Investor Forum website.

About Advaxis, Inc.

Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live attenuated Listeria monocytogenes (Lm) that are bio-engineered to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to Lm to the cancer, itself.

ADXS-HPV, Advaxis’ first construct is being evaluated in 4 Phase 2 clinical trials for HPV associated diseases (CIN 2/3, cervical cancer, and head & neck cancer) with over 130 patients dosed to date. Over fifteen (15) distinct constructs are in various stages of development, either developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others. For more information please visit: advaxis.com | Facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties.  The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance.  Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company’s actual results in future periods to differ materially from what is currently anticipated.  Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission.  The Company cannot guarantee its future results, levels of activity, performance or achievements.

For Further Information:

Diana Moore

Director, Investor Relations & Business Development

Advaxis, Inc.

dmoore@advaxis.com

609.452.9814

Princeton, NJ – October 13, 2011 – Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been chosen by Windhover and Jonathon Fendelman of Campbell Alliance as one of the 2011 Top 10 Most Interesting Oncology Projects to Watch for the Advaxis ADXS-HPV immunotherapy program.

Tom Moore and Dr. John Rothman will present at Windhover’s Therapeutic Area Partnerships meeting taking place on November 30-Dec 2, 2011 at the Westin Copley, Boston.

“Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees considered the most attractive oncology opportunities the industry has to offer,” said David Cassak, vice president, content, Windhover Conferences, a division of Elsevier Business Intelligence. “Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability.”

About Windhover     

Windhover Information Inc., an Elsevier company, has led the field in providing analysis of the healthcare industry to decision-makers at
all levels since the founding of its flagship publication, IN VIVO, The Business & Medicine Report, in 1983. Windhover provides its
information and analysis in many formats, including print, electronic databases, international conferences and webinars.
For more information please visit: http://www.windhover.com.

About Windhover’s Therapeutic Area Partnerships Meeting

Windhover Information’s 6th Annual Therapeutic Area Partnerships is the industry’s most targeted and efficient partnering meeting for life science companies seeking partnerships in the top therapeutic areas: Oncology, Cardiovascular/Metabolic, Neuroscience, Infectious, Inflammatory Diseases and more other hot therapeutic areas. For more information please visit: http://www.windhover.com/content/conferences/TA10-top10.html.

About ADXS-HPV

ADXS-HPV is an immunotherapy that is designed to treat human papilloma virus (HPV) associated diseases. Today, HPV is the most prevalent sexually transmitted disease in the US and the cause of cervical cancer, head and neck cancers of the oral pharynx, as well as a percentage of penile, vulvar, and anal cancers. ADXS-HPV is currently being evaluated in four Phase 2 clinical trials including two trials in cervical cancer, one in head and neck cancer, and one in CIN 2/3 (cervical intraepithelial neoplasia). Over 130 patients have been dosed to date in ADXS-HPV clinical trials.

About Advaxis, Inc.

Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live attenuated Listeria monocytogenes (Lm) that are bio-engineered to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to Lm to the cancer, itself.

ADXS-HPV, Advaxis’ first construct is being evaluated in 4 Phase 2 clinical trials for HPV associated diseases (CIN 2/3, cervical cancer, and head & neck cancer) with over 130 patients dosed to date. Over fifteen (15) distinct constructs are in various stages of development, either developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others. For more information please visit: advaxis.com | Facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties.  The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance.  Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company’s actual results in future periods to differ materially from what is currently anticipated.  Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission.  The Company cannot guarantee its future results, levels of activity, performance or achievements.

For Further Information:

Diana Moore

Director, Investor Relations & Business Development

Advaxis, Inc.

dmoore@advaxis.com

609.452.9814

PRINCETON, N.J. – October 11, 2011 – Advaxis, Inc., (OTCBB:ADXS) a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”) on November 22^nd, 2011 to discuss the initial clinical development plan for ADXS-HER2, a construct for the treatment of HER2 expressing cancers.

ADXS-HER2 is manufactured by Vibalogics, located in Cuxhaven, Germany.

A pre-IND meeting is conducted to develop mutual understanding and agreement between the FDA and the Company regarding the content needed to assess manufacturing, toxicology, pre-clinical and rationale to support a first in humans clinical trial. Once an IND is submitted, the FDA has 30 days to comment before the Company can begin Phase 1 trials. The Company plans to file the IND application early in 2012 to initiate a Phase 1/2 safety study in humans.

“ADXS- HER2 immunotherapy is the third Lm-LLO agent Advaxis is advancing to the clinic,” commented Dr. John Rothman, Executive VP of Advaxis. “It uses a proprietary chimeric form of the HER2 antigen (cHER2) that gives it the potential to overcome “escape mutations” in cancer, and has shown encouraging results in mouse models for HER2 positive breast cancer and preliminary data in brain cancer. Advaxis constructs are designed to redirect the powerful immune response we all have to Listeria to selected tumor associated antigens such as those over expressing HER2.”

About HER2

HER2 (human epidermal growth factor receptor 2) is a gene which is over expressed in a percentage of certain types of cancers such as breast, stomach, bladder, pancreatic, brain, and ovarian. The American Cancer Society estimates that in 2011 in the US there will be 230,480 diagnoses of invasive breast cancer, 21,520 new cases of stomach cancer, 69,250 new cases of bladder cancer, 44,030 new cases of pancreatic cancer, 22,340 new cases of brain/spinal cord cancer, and 21,900 new cases of ovarian cancer.

About Advaxis, Inc.

Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live attenuated Listeria monocytogenes (Lm) that are bio-engineered to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to Lm to the cancer, itself.

ADXS-HPV, Advaxis’ first construct is being evaluated in 4 Phase 2 clinical trials for HPV associated diseases (CIN 2/3, cervical cancer, and head & neck cancer) with over 130 patients dosed to date. Over fifteen (15) distinct constructs are in various stages of development, either developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others. Additional information can be found at: advaxis.com | facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties.  The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance.  Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company’s actual results in future periods to differ materially from what is currently anticipated.  Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission.  The Company cannot guarantee its future results, levels of activity, performance or achievements.

For Further Information:

Diana Moore

Director, Investor Relations & Business Development

Advaxis, Inc.

dmoore@advaxis.com

609.452.9814

Princeton, NJ – September 6, 2011 – Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced today that the Company’s Chairman and CEO, Thomas A. Moore, will present a corporate overview of Advaxis at the Rodman & Renshaw 13^th Annual Healthcare Conference, Tuesday, September 13th at 2:25p.m. EST in the Starlight North room at the Waldorf=Astoria in New York.

A link to a live webcast of the presentation will be available on the Company’s website and will be archived for 90 days. 

About Advaxis, Inc.

Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Our novel platform technology is designed to generate a comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. Today, the Company has over fifteen (15) distinct constructs in various stages of development, directly developed by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others. Additional information can be found at: advaxis.com | facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties.  The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance.  Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company’s actual results in future periods to differ materially from what is currently anticipated.  Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission.  The Company cannot guarantee its future results, levels of activity, performance or achievements.

For Further Information:

Diana Moore

Director, Investor Relations & Business Development

Advaxis, Inc.

dmoore@advaxis.com

609.452.9814